Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Abstract

OBJECTIVE Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and may cause fewer of these adverse effects. We compared the… (More)
DOI: 10.2337/dc11-0606

Topics

4 Figures and Tables

Cite this paper

@article{Nauck2011DapagliflozinVG, title={Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.}, author={Michael A Nauck and Stefano Del Prato and Juris J Meier and Santiago Dur{\'a}n-Garc{\'i}a and Katja Rohwedder and Martina Elze and Shamik J. Parikh}, journal={Diabetes care}, year={2011}, volume={34 9}, pages={2015-22} }